Results

Total Results: 1,651 records

Showing results for "described".

421. Disposition of Comments Technical Brief 30 Assessment Tools for Palliative Care (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/palliative-care-tools-disposition.pdf
     May 04, 2017 - of relevant issues and gaps” 24 Peer Reviewer #3 Methods The Methods section overall clearly described … that it was important to solicit their opinions on all aspects of the project given their role as described … clinical assessment, QI, Research, Accountability) The intended use of the tools was not generally described … We have clarified for pain and dyspnea: “As described in the National Consensus Guidelines for Quality … Quality of life tools do include physical functioning, as described in the definition in the beginning

422. Disposition of Comments Technical Brief 30 Assessment Tools for Palliative Care (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/palliative-care-tools-disposition.pdf
     May 04, 2017 - of relevant issues and gaps” 24 Peer Reviewer #3 Methods The Methods section overall clearly described … that it was important to solicit their opinions on all aspects of the project given their role as described … clinical assessment, QI, Research, Accountability) The intended use of the tools was not generally described … We have clarified for pain and dyspnea: “As described in the National Consensus Guidelines for Quality … Quality of life tools do include physical functioning, as described in the definition in the beginning

423. Disposition of Comments for CER 195 Management of Uterine Fibroids (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-195-disposition-comments-uterine-fibroids.pdf
     December 14, 2017 - We revised SOE here and later in the report as described below in the reply to comments in the more … Ullipristal is described as follows: Ulipristal acetate (Ella®, Esmya®) is a selective progesterone … We reported potential harms as described in the included studies (now including Donnez). … We reported potential harms as described in the included studies (now including Donnez). … The characteristics of the studies are clearly described, with key messages clearly communicated.

424. Disposition of Comments for CER 201 Effectiveness of Indoor Allergen Reduction in the Management of Asthma (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-201-indoor-allergen-asthma-disposition-comments.pdf
     February 15, 2018 - Thus, we encourage the Agency to finalize this Draft Report with the suggested modifications described … All of these approaches are now described more fully in the Results, and and the limitations of our … As described in the Methods, we used AHRQ EPC methods to guide our assessment of the body of evidence … Study characteristics are well described. Thank you. … All of these approaches are not described more fully in the Results, and the limitations of our analysis

425. Disposition of Comments for CER 208 Treatment for Bipolar Disorder in Adults A Systematic Review (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-208-bipolar-adults-disposition-comments.pdf
     August 07, 2018 - There are some issues with the search strategy as described in the general comments attachment. … In several locations in the document, study findings are described as "mixed" but no other details or … Currently, the study is described in one part of the document but not others. … Results – Overall Peer Reviewer #5 The included studies are well-described and the informative … “Handling of data from missing persons not described” Refer to figure 1.

426. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/treatment-resistant-depression_disposition-comments.pdf
     September 01, 2011 - We believe this rational is clearly described in the Introduction at the end of the “Patient Populations … BA 25) has substantial efficacy in experimental studies, yet this is not described. … The characteristics of the studies are clearly described and key messages are stated explicitly and … The limitations of the review/studies are described adequately. … described and not a part of eligibility criteria for study).

427. pediatric-EHR-protocol-140818 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/pediatric-ehr_research-protocol.pdf
     January 01, 2014 - policy makers, and professional organizations such as the American Academy of Pediatrics (AAP) have described … meet pediatric functionality and workflow demands could be potentially dangerous.10 Some studies have described … Healthcare Research and Quality (AHRQ),41 Health Level 7 (HL7) International,42 and the AAP3 have described

428. Evidence Report on the (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/labor-nitrous-oxide_research-protocol.pdf
     August 24, 2011 - used nitrous oxide (likely an overestimate considering how few U.S. facilities offer this method as described … Bishop has briefly described the UCSF practices in ―Administration of Nitrous Oxide in Labor: Expanding … (e.g., Nitronox) is the most common method of nitrous oxide administration for labor pain relief described

429. Comparative Effectiveness and Safety of New Therapies (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/diabetes-glucose-control_research.pdf
     July 01, 2010 - We categorized patients by medication use and by their first fill-date of exenatide, and described the … For descriptive purposes, we reported the means and percentages of the variables described above. … After creating the cohort, as described in the methods, we studied the 3,225 patients who filled exenatide

430. Evidence Report on the (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/weight-loss-surgery_research-protocol.pdf
     December 14, 2010 - Population(s): Demographic subsets of the populations described in KQ1. … for this Comparative Effectiveness Review, with the five key questions depicted within the context described … Studies will be included that address the populations, interventions, comparators, and outcomes described

431. Slide 1
     effectivehealthcare.ahrq.gov/sites/default/files/study-design-considerations-chapter-2.pptx
     January 01, 2013 - Commonly used comparative effectiveness research study designs are described, and key design features … exposure classification (heart transplant or not) should not be attributed to the heart transplant and is described … Approaches to empirical identification of confounders should be described if planned.

432. Quality-Gap-Palliative-Hospice Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/quality-gap-palliative-hospice_executive.pdf
     October 01, 2012 - We included 90 studies described in 96 articles in the review (Figure B). … We described the information abstracted in a systematic manner but did not conduct any meta-analyses … Coordination of Care, and Transitions Key Question 1a: Evidence About Target We found 23 studies described

433. MS Protocol draft_12_12-13 clean[2] (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/multiple-sclerosis_research-protocol.pdf
     December 17, 2013 - review based on the PICOTS framework outlined in Section II and the study-specific inclusion criteria described … www.effectivehealthcare.ahrq.gov Published online: December 17, 2013 9 results to planned analysis described … in trial registries and/or the methodology section of the publication as described in a recent AHRQ

434. Disposition of Comments for Treatment Strategies for Patients With Peripheral Artery Disease (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/peripheral-artery-disease-treatment_disposition-comments.pdf
     May 29, 2013 - The search, inclusion and exclusion criteria are well described. … Peer Reviewer 3 Methods Very sound methods that are clearly described. Thank you. … Outcome measures are appropriate and described adequately. … TEP Member 4 Results Characteristics of the studies are clearly described in the report and (in a more … The numerous and serious limitations of the studies/review are clearly described (best in Executive

435. Biomarkers for Assessing and Managing Iron Deficiency Anemia in Late-Stage Chronic Kidney Disease: Future Research Needs (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/chronic-kidney-disease-anemia_research.pdf
     January 01, 2013 - All gaps described in Key Questions 2, 3, and 4 are applicable to this overarching question. … Criteria for Prioritization Stakeholders (described in the next section) were asked to consider four … All gaps described in Key Questions 2, 3, and 4 are applicable to this overarching question. … Criteria for Prioritization Stakeholders (described in the next section) were asked to consider four … generally accepted reference standard tests for determining iron deficiency in the setting of CKD (described

436. Dia 1 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/ijzerman_ahrq-webinar-mcda.pdf
     January 01, 2011 - Dia 1 1 Integrating stakeholder preferences in comparative effectiveness research using multi-criteria decision analysis (MCDA) and Conjoint Analysis (CA) Maarten J. IJzerman, PhD Professor and chair, department Health Technology & Services Research m.j.ijzerman@utwente.nl Multiple endpoints in …

437. Schedule of Visits and Use of Telemedicine for Routine Antenatal Care: A Systematic Review Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/antenatal-care.pdf
     January 01, 2020 - As described below, we will evaluate the strength of evidence (SoE) for these outcomes. … Qualitative studies (KQ 3) We will search for qualitative studies as part of the overall search described … extended into the grey literature (evidence from sources not identified using standard methods, as described … Each study will be described in summary and evidence tables presenting study design features, study

438. Disposition of Comments for CER 211: Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-211-rheumatoid-arthritis-disposition-comments.pdf
     December 20, 2018 - Peer Reviewer #1 Evidence Summary ES-3, lines 26-32 Clarify all DAS28 scores described are baseline … The ranges of DAS28 scores described for each drug category capture both mean and median values of our … If one changes and others do not, this is described in the detailed results. … Peer Reviewer #3 Introduction Nulliparity was described as a risk factor for RA (page 1, line 20) … Peer Reviewer #3 Methods Throughout the document, studies involving MTX are described and results

439. EHC Protocol: Addressing Social Isolation To Improve Health of Older Adults: A Rapid Evidence Review (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/high-risk-drugs-protocol.pdf
     July 27, 2023 - • Unspecified study designs or comparison group not described.

440. CER 221 Disposition of Comments: Pharmacologic and Nonpharmacologic Therapies in Adult Patients With Exacerbation of COPD (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-221-copd-comments_0.pdf
     October 11, 2019 - page 22+): The content is not linked to KQ nor SOE descriptions; suggest replacing with the table described